Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
367-02-010 ISMRM Abstract

Dynamic evaluation of low-molecular-weight heparin enhancing immunotherapy in colon cancer models by multiparametric MRI

Primary: Preclinical Animal & in vitro MR - Other Preclinical
Secondary: Preclinical Animal & in vitro MR - Small Animals
367-02-010 · Cancer Detection and Therapies · Monday, 11 May, 9:15 AM–10:10 AM · Digital Posters Row H
Keywords: Multi-parametric MRI Colon cancer Immune checkpoint inhibitors Vascular normalization Low-molecular-weight heparin
Accepted
Xinhui Chen 1,2, Jiayang Wu1,2, Dong Zhang1,2, Geni Ye3, JiFeng Chen2, Xiaocong Ma1,2, wei cui4, Liangping Luo5, Changzheng Shi1,2, Xi Xu1,2
1Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, China
2The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, The First Affiliated Hospital of Jinan University, Guangzhou, China
3College of Pharmacy, Jinan University, Guangzhou, China
4MRI Research, GE Healthcare, Beijing, China
5Department of Radiology and Nuclear Medicine, The Fifth Affiliated Hospital of Jinan University (Shenhe People’s Hospital), China
Presenting Author: Xinhui Chen

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Bailey CE, Hu C, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the united states, 1975-2010. JAMA Surg. 2015 2015 Jan;150(1):17-22. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=25372703&query_hl=1 doi: 10.1001/jamasurg.2014.1756 [doi]
2. Li J, Wu C, Hu H, Qin G, Wu X, Bai F, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023 2023 Jun 12;41(6):1152-69. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=37172580&query_hl=1 doi: 10.1016/j.ccell.2023.04.011 [doi]
3. Remiker AS, Palumbo JS. Mechanisms coupling thrombin to metastasis and tumorigenesis. Thromb Res. 2018 2018 Apr;164 Suppl 1:S29-33. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=29703481&query_hl=1 doi: 10.1016/j.thromres.2017.12.020 [doi]
4. Garcia-Escobar I, Beato-Zambrano C, Munoz Langa J, Brozos Vazquez E, Obispo Portero B, Gutierrez-Abad D, et al. Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients? Clin Transl Oncol. 2018 2018 Sep;20(9):1097-108. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=29470777&query_hl=1 doi: 10.1007/s12094-018-1835-2 [doi]
5. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019 2019;14(2):89-103. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=31616522&query_hl=1 doi: 10.5114/pg.2018.81072 [doi]
6. Wei F, Su Y, Quan Y, Li X, Zou Q, Zhang L, et al. Anticoagulants enhance molecular and cellular immunotherapy of cancer by improving tumor microcirculation structure and function and redistributing tumor infiltrates. Clin Cancer Res. 2023 2023 Jul 5;29(13):2525-39. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=36729148&query_hl=1 doi: 10.1158/1078-0432.CCR-22-2757 [doi]
7. Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, et al. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018 2018 Oct;52(4). Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=30262574&query_hl=1 doi: 10.1183/13993003.01220-2018 [doi]
8. Esteves M, Monteiro MP, Duarte JA. The effects of vascularization on tumor development: a systematic review and meta-analysis of pre-clinical studies. Crit Rev Oncol Hematol. 2021 2021 Mar;159:103245. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=33508446&query_hl=1 doi: 10.1016/j.critrevonc.2021.103245 [doi]
9. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 2012 Oct 23;109(43):17561-66. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=23045683&query_hl=1 doi: 10.1073/pnas.1215397109 [doi]
10. Nolan-Stevaux O, Truitt MC, Pahler JC, Olson P, Guinto C, Lee DC, et al. Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes. Genes Cancer. 2010 2010 Feb;1(2):125-41. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20975924&query_hl=1 doi: 10.1177/1947601909358722 [doi]
11. Sprugnoli G, Monti L, Lippa L, Neri F, Mencarelli L, Ruffini G, et al. Reduction of intratumoral brain perfusion by noninvasive transcranial electrical stimulation. Sci Adv. 2019 2019 Aug;5(8):eaau9309. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=31453319&query_hl=1 doi: 10.1126/sciadv.aau9309 [doi]
12. Denton CC, Detterich JA, Coates TD, Wood JC. Kidney iron deposition by r2* is associated with haemolysis and urinary iron. Br J Haematol. 2021;193(3):633-36. Available from: https://onlinelibrary.wiley.com/doi/10.1111/bjh.17085 https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17085 doi: 10.1111/bjh.17085 [doi]
13. Lau D, McLean MA, Priest AN, Gill AB, Scott F, Patterson I, et al. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma. J Immunother Cancer. 2021 2021 Sep;9(9). Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=34561275&query_hl=1 doi: 10.1136/jitc-2021-003125 [doi]
14. Bao X, Bian D, Yang X, Wang Z, Shang M, Jiang G, et al. Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer. Eur Radiol. 2023;33(12):9182-93. Available from: https://link.springer.com/10.1007/s00330-023-09813-8 https://link.springer.com/content/pdf/10.1007/s00330-023-09813-8.pdf doi: 10.1007/s00330-023-09813-8 [doi]
15. Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017 2017 Apr 13;544(7649):250-54. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=28371798&query_hl=1 doi: 10.1038/nature21724 [doi]
16. Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, et al. Increased CD8+ t-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in hepatocellular carcinoma. J Natl Cancer Inst. 2022 2022 Sep 9;114(9):1301-05. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=35288743&query_hl=1 doi: 10.1093/jnci/djac051 [doi]
17. Bauer AT, Gorzelanny C, Gebhardt C, Pantel K, Schneider SW. Interplay between coagulation and inflammation in cancer: limitations and therapeutic opportunities. Cancer Treat Rev. 2022 2022 Jan;102:102322. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=34922151&query_hl=1 doi: 10.1016/j.ctrv.2021.102322 [doi]
18. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-l1 blockade by contributing to exclusion of t cells. Nature. 2018 2018 Feb 22;554(7693):544-48. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=29443960&query_hl=1 doi: 10.1038/nature25501 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/367-02-010